Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
posted on
Oct 26, 2020 08:26AM
"We look forward to providing additional data on the effects of apabetalone on COVID-19 infection in our upcoming American Heart Association presentation on November 13, 2020.”